NasdaqGM:CRMDPharmaceuticals
CorMedix (CRMD): Evaluating Valuation After a Strong Multi‑Year Share Price Run
CorMedix (CRMD) has quietly put together an impressive run, with the stock up about 48% this year and more than tripling over the past 3 years, grabbing investors' attention again.
See our latest analysis for CorMedix.
That strength has not been a one off move, with a 30 day share price return of about 24% and a three year total shareholder return above 220% pointing to clear positive momentum.
If CorMedix is on your radar, this could also be a good moment to explore other healthcare names...